Alnylam Pharma (ALNY) Tops Q3 EPS by 15c, Misses on Revenue, Offers FY22 Revenue Guidance
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $293.52 +0.74%
EPS Growth %: +409.4%
Financial Fact:
Net loss per common share - basic and diluted: -1.05
Today's EPS Names:
DTGI, OCCI, MAYS, More
EPS Growth %: +409.4%
Financial Fact:
Net loss per common share - basic and diluted: -1.05
Today's EPS Names:
DTGI, OCCI, MAYS, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q3 EPS of ($1.58), $0.15 better than the analyst estimate of ($1.73). Revenue for the quarter came in at $264.3 million versus the consensus estimate of $293.08 million.
GUIDANCE:
Alnylam Pharma sees FY2022 revenue of $870-930 million, versus the consensus of $1.02 Billion.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Alnylam Pharmaceuticals (ALNY) PT Lowered to $470 at H.C. Wainwright
- Concentrix Corporation (CNXC) Misses Q2 EPS by 1c; Guides lower than expectations
- Apogee Enterprises (APOG) Tops Q1 EPS by 16c, Beats on Revenue; Offers FY27 Guidance
Create E-mail Alert Related Categories
Earnings, Guidance, Hot EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
